EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Large-scale proteomics profiling of peripheral blood of DM1 patients identifies biomarkers for disease severity and functional capacity

Daniël van As iD, Tine Claeys, Renee Salz, Delphi Van Haver, Sara Dufour, Amber van Deelen, Jolein Gloerich, Ralf Gabriels, Pieter Jan Volders, Vera Dobelmann, Andrea Gangfuss, Tobias Ruck und 13 weitere

Journal of Neuromuscular Diseases · 2026

DOI: 10.1177/22143602251410443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, 2026. Verfasst von Daniël van As und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Proteomics, Myotonic Dystrophy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada Foundation for Innovation, ZonMw, Canada Research Coordinating Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Myotonic Dystrophy Type 1 (DM1), the most common genetic neuromuscular disorder in adults, poses significant challenges for drug development due to its multisystem nature and high clinical variability in symptoms and disease progression. With a growing number of therapies entering clinical trials, this study addresses the urgent need for biomarkers that can serve as surrogate endpoints.

Methods

We profiled 437 serum samples from adult DM1 patients collected at two timepoints of the OPTIMISTIC trial using bottom-up mass spectrometry with data-independent acquisition. Associations between protein expression, the disease-causing CTG-repeat and 25 clinical outcome measures were studied using linear mixed-effect models. All key study findings were validated in an independent cohort of 69 DM1 patients and 10 healthy controls.

Results

Of the 259 identified proteins, 161 showed significant associations with the CTG-repeat length (FDR < 5%). Hypogammaglobulinemia was confirmed and shown to be worse in severely affected patients. A strong proteomic signature was associated with clinical measures of functional capacity, with the 6-Minute Walk Test showing the strongest signal (70 associations, FDR < 5%). These novel associations reveal a compelling link between chronic inflammation and reduced functional capacity. A machine learning algorithm identified a minimal set of 13 proteins robustly reflecting both the underlying genetic defect and functional capacity.

Conclusions

DM1 induces a broad disease fingerprint in the serum proteome, predominantly affecting proteins of the immune system. A carefully selected panel of proteins showed the greatest potential to meet the statistical criteria required for surrogate endpoints in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsMyotonic DystrophyHumansBiomarkersFemaleAdultSeverity of Illness IndexMaleMiddle AgedWalk Test

Stichwörter der Autor:innen

DM1biomarkersbloodcomplement systemmyotonic dystrophy type 1proteinsserum

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.
  • VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium.
  • Department of Biomolecular Medicine, Faculty of Medicine and Healthy Sciences, Ghent University, Ghent, Belgium.
  • Translational Metabolic Laboratory, Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Limburg Clinical Research Center (LCRC), UHasselt, Diepenbeek, Belgium.

ORCID-Profile: Daniël van As

Förderung

  • Canada Foundation for Innovation
  • ZonMw
  • Canada Research Coordinating Committee
  • Myositis-Netz
  • Canadian Institutes of Health Research
  • European Commission
  • Deutsche Gesellschaft für Muskelkranke
  • Fonds de Recherche du Québec - Santé

Zitieren

APA

van As, D., Claeys, T., Salz, R., Haver, D. V., Dufour, S., Deelen, A. V., Gloerich, J., Gabriels, R., Volders, P. J., Dobelmann, V., Gangfuss, A., Ruck, T., Gourdon, G., Duchesne, E., Gagnon, C., Roos, A., Gool, A. V., Impens, F., Martens, L., …, & OPTIMISTIC consortium, ReCognitION consortium (2026). Large-scale proteomics profiling of peripheral blood of DM1 patients identifies biomarkers for disease severity and functional capacity. Journal of Neuromuscular Diseases. https://doi.org/10.1177/22143602251410443

Vancouver

van As D, Claeys T, Salz R, Haver DV, Dufour S, Deelen AV, et al. Large-scale proteomics profiling of peripheral blood of DM1 patients identifies biomarkers for disease severity and functional capacity. Journal of Neuromuscular Diseases. 2026. doi:10.1177/22143602251410443

BibTeX
@article{vanAs2026,
  author = {van As, Daniël and Claeys, Tine and Salz, Renee and Haver, Delphi Van and Dufour, Sara and Deelen, Amber van and Gloerich, Jolein and Gabriels, Ralf and Volders, Pieter Jan and Dobelmann, Vera and Gangfuss, Andrea and Ruck, Tobias and Gourdon, Genevieve and Duchesne, Elise and Gagnon, Cynthia and Roos, Andreas and Gool, Alain van and Impens, Francis and Martens, Lennart and Lochmüller, Hanns and Schoser, Benedikt and Bassez, Guillaume and van Engelen, Baziel Gm and 't Hoen, Peter Ac and OPTIMISTIC consortium, ReCognitION consortium, OPTIMISTIC consortium, ReCognitION consortium},
  title = {Large-scale proteomics profiling of peripheral blood of DM1 patients identifies biomarkers for disease severity and functional capacity},
  journal = {Journal of Neuromuscular Diseases},
  year = {2026},
  doi = {10.1177/22143602251410443}
}
Kostenlos starten →